UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 3, 2014

 

REGENERX BIOPHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware   001-15070   52-1253406
(State or Other Jurisdiction   (Commission   (IRS Employer
of Incorporation)   File Number)   Identification No.)

 

     
15245 Shady Grove Road, Suite 470, Rockville, MD   20850
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (301) 208-9191

 

 
(Former Name or Former Address, if Changed Since Last Report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  

 

 

1
 

 

Item 1.01  Entry into a Material Definitive Agreement.

 

The information set forth in Item 3.02 is incorporated by reference herein.

 

Item 2.03  Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

 

The information set forth in Item 3.02 is incorporated by reference herein.

 

Item 3.02  Unregistered Sales of Equity Securities.

 

Private Placement of Convertible Notes

 

On January 7, 2014, RegeneRx Biopharmaceuticals, Inc. (the “Company”) completed a private placement of convertible notes (the “Notes”) with five accredited investors (each, an “Investor,” collectively, the “Investors”), raising an aggregate of $55,000 in gross proceeds.  The Notes were issued pursuant to a Convertible Note Purchase Agreement (the “Security Purchase Agreement”), between the Company and the Investors, the full text of which is filed herewith as Exhibit 10.1 to this Form 8-K.  The full text of the form of Convertible Promissory Note is filed herewith as Exhibit 4.1 to this Form 8-K.

 

Convertible Promissory Notes.   The key terms of the Notes are summarized below.  The Notes will pay interest at a rate of 5% per annum, mature 60 months after their date of issuance and are convertible into shares of our common stock at a conversion price of $0.06 per share (subject to adjustment as described in the Notes) at any time prior to repayment, at the election of the Investor.  In the aggregate, the Notes are initially convertible into up to 916,667 shares of our common stock.  

 

At any time prior to maturity of the Notes, with the consent of the holders of a majority in interest of the Notes, we may prepay the outstanding principal amount of the Notes plus unpaid accrued interest without penalty.  Upon the commission of any act of bankruptcy by the Company, the execution by the Company of a general assignment for the benefit of creditors, the filing by or against the Company of a petition in bankruptcy or any petition for relief under the federal bankruptcy act or the continuation of such petition without dismissal for a period of 90 days or more, or the appointment of a receiver or trustee to take possession of the property or assets of the Company, the outstanding principal and all accrued interest on the Notes will accelerate and automatically become immediately due and payable.

 

Investors . The Investors in the offering included three directors of the Company, Allan L. Goldstein, the Company’s Chairman and chief scientific officer, Joseph C. McNay, an outside director and L. Thompson Bowles, an outside director. The principal amounts of their respective Notes are as set forth below:

 

Investor Note Principal
Joseph C. McNay $25,000
Allan L. Goldstein $10,000
L. Thompson Bowles $5,000

 

 

Use of Proceeds.   We intend to use the proceeds from the offering to pay certain accrued liabilities and for working capital, operating expenses and general corporate purposes.  Based on current estimates, we anticipate that our existing financial resources, including the net proceeds from this offering, will be adequate to continue to conduct our business into February 2014.  We will need to raise additional capital prior to the maturity date to repay the Notes and to continue operating our business.

 

Securities Act Exemption.   The offering was exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”) in accordance with Section 4(a)(2) under the Securities Act and Rule 506 promulgated thereunder as an offering made solely to “accredited investors” as defined under the Securities Act.  The Company obtained representations and warranties from the Investors in the Security Purchase Agreement to support the Company’s reliance on this exemption.

 

2
 

 

The foregoing descriptions of the terms of the Notes and the Security Purchase Agreement does not purport to be complete and are qualified in their entirety by reference to the text of these documents filed as exhibits hereto which are incorporated herein by reference.

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

As reported on a Current Report on Form 8-K filed on January 6, 2012, the Company previously entered into letter agreements with each of J.J. Finkelstein, the Company’s President and Chief Executive Officer, David Crockford, the Company’s vice president of clinical and regulatory affairs, and Allan Goldstein, the Company’s chief scientific advisor and a member of the Company’s board of directors, relating to their employment with the Company. In addition, the Company entered into change of control agreements with each of Mr. Finkelstein, Mr. Crockford and Dr. Goldstein, providing for the payment of severance obligations upon specified terminations of employment.

 

As previously reported, between July 2, 2012 and July 5, 2013, the the Company and each officer entered into, amendments to each of the letter agreements and change in control agreements to, among other things, extend their terms through December 31, 2013.

 

On January 7, 2014, the Company entered into amended letter agreements with Mr. Finkelstein and Dr. Goldstein which amended their temporary employment letters and the amended and restated change in control agreements to extend their respective terms through June 30, 2014.

 

Under the letter agreements, as extended, Mr. Finkelstein and Dr. Goldstein will continue to receive a salary at a rate of $50.00 per hour, subject to deductions and withholdings. Mr. Finkelstein’s typical work schedule will continue to be up to 100 hours per month and Dr. Goldstein’s typical work schedule will continue to be up to 32 hours per month, in each case with no guaranteed minimum number of hours. In accordance with the letter agreements, the employment termination date for each officer will be June 30, 2014, unless terminated prior to that date by such officer or by the Company.

 

Under the amended and restated change in control agreements, each officer is eligible to receive severance payments upon specified change in control transactions. If a Change in Control (as defined in the agreement) is consummated by June 30, 2014, and prior to June 30, 2014, or within 12 months following the Change in Control, the Company terminates the officer’s employment for any reason, other than Cause (as defined in the agreement) or the officer’s death or disability, or if the officer resigns for Good Reason (as defined in the agreement), then: 

 

· on the effective date of the Change in Control, any outstanding stock option or other equity award held at such time by the officer under the terms of the Company’s equity incentive plans shall become fully vested and exercisable in full immediately before such Change in Control transaction and contingent upon its effectiveness; and

 

· the officer will be eligible to receive a severance payment equal to up to six months of his base salary in effect as of November 30, 2011, which severance amount will be calculated as set forth in the table below based upon the Net Proceeds (as defined in the agreement) from the Change in Control and will be payable in two equal installments, with the first payment occurring on the 60 th  day after the effective date of the Change in Control or, if later, the date of the officer’s separation from service, and the second installment occurring 60 days after the initial payment date.

 

3
 

 

 

Net Proceeds   Severance Amount
Up to $1,000,000   1 month
$1,000,000 through $1,999,999.99   1 month
$2,000,000 through $2,999,999.99   2 months
$3,000,000 through $3,999,999.99   3 months
$4,000,000 through $4,999,999.99   4 months
$5,000,000 through $5,999,999.99   5 months
$6,000,000 and above   6 months

 

 

Each officer will be required to execute a general release and waiver of all legal claims prior to receiving any severance payment. The compensation provided pursuant to the change in control agreements will be the only severance benefits to which Mr. Finkelstein or Dr. Goldstein may be entitled upon termination of their employment with the Company.

 

On January 3, 2014, Mr. Crockford informed the Company that he was electing to not continue his temporary employment with the Company. Mr. Crockford and the Company are currently discussing a potential consulting arrangement.

 

Item 9.01 Financial Statements and Exhibits.

(d)   Exhibits

 

     
Exhibit    
Number   Description
4.1   Form of Convertible Promissory Note
     
10.1  

Convertible Note Purchase Agreement 

     
10.2   Letter Agreement between the Company and J.J. Finkelstein, dated January 7, 2014.
     
10.3   Letter Agreement between the Company and Allan L. Goldstein, dated January 7, 2014.
     

 

4
 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  REGENERX BIOPHARMACEUTICALS, INC.
   
   
Date:  January 9, 2014  
  By: /s/ J.J. Finkelstein
  Name:  J.J. Finkelstein
  Title: President and Chief Executive Officer

 

5
 

  

EXHIBIT INDEX

     
Exhibit    
Number   Description
4.1   Form of Convertible Promissory Note
     
10.1  

Convertible Note Purchase Agreement 

     
10.2   Letter Agreement between the Company and J.J. Finkelstein, dated January 7, 2014.
     
10.3   Letter Agreement between the Company and Allan L. Goldstein, dated January 7, 2014.

 

6

 

Exhibit 4.1

 

THIS CONVERTIBLE PROMISSORY NOTE AND THE SECURITIES ISSUABLE UPON THE CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

 

 

 

CONVERTIBLE PROMISSORY NOTE

 

 

$________   January 7, 2014
    Rockville, Maryland

 

 

For value received, RegeneRx Biopharmaceuticals, Inc., a Delaware corporation (the “ Company ”), promises to pay to ____________ (the “ Holder ”), the principal sum of $________. Interest shall accrue from the date of this Convertible Promissory Note (this “ Note ”) on the unpaid principal amount at a rate equal to five percent (5%) per annum. This Note is one of a series of Convertible Promissory Notes containing substantially identical terms and conditions issued pursuant to that certain Convertible Note Purchase Agreement dated as of January 7, 2014. Such Notes are referred to herein as the “ Notes ” and the holders thereof are referred to herein as the “ Holders ”. This Note is subject to the following terms and conditions.

 

1. Maturity . Unless converted or repaid pursuant to Section 2 or Section 3, the entire unpaid principal sum of this Note, together with accrued and unpaid interest thereon, will be payable upon the written demand of the Holder at any time after January 6, 2019 (the “ Maturity Date ”). Subject to Section 3, interest shall accrue on this Note but shall not be due and payable until the written demand of the Holder on or after the Maturity Date. Notwithstanding the foregoing, the entire unpaid principal sum of this Note, together with accrued and unpaid interest thereon, shall become immediately due and payable upon the commission of any act of bankruptcy by the Company, the execution by the Company of a general assignment for the benefit of creditors, the filing by or against the Company of a petition in bankruptcy or any petition for relief under the federal bankruptcy act or the continuation of such petition without dismissal for a period of ninety (90) days or more, or the appointment of a receiver or trustee to take possession of the property or assets of the Company.

 

 

 
 

 

 

2. Conversion .

 

(a) Optional Conversion . At any time prior to repayment of this Note, the outstanding principal amount of this Note and accrued but unpaid interest on this Note (the “ Conversion Amount ”) may, at the option of the Holder, be voluntarily converted into shares of common stock, $0.001 par value per share (the “ Common Stock ”) of the Company or such other securities or property for which this Note may become convertible as a result of any adjustment described in Section 2(b). The number of shares of Common Stock to be issued upon such conversion shall be equal to (i) the Conversion Amount divided by (ii) the Conversion Price (as defined below). The Conversion Price shall initially be equal to $0.06 per share.

 

(b) Adjustment .

 

(i) So long as this Note is outstanding, if the Company shall issue any Common Stock (including any accompanying warrant) prior to the complete conversion or payment of this Note, for a consideration per share that is less than the Conversion Price that would be in effect at the time of such issue, then, and thereafter successively upon each such issuance, the Conversion Price shall be reduced to such other lower issue price and Note Holder shall also receive a warrant, if any, on the same terms (including, but not limited to, ratio of shares under the warrant to dollars invested and exercise price) as the participants in the lower price transaction triggering the Conversion Price adjustment.  For purposes of this adjustment, the issuance of any security or debt instrument of the Company carrying the right to convert such security or debt instrument into Common Stock shall result in an adjustment to the Conversion Price upon the issuance of the above-described security if such issuance is at a price lower than the then applicable Conversion Price.

 

(ii) In the event of changes in the outstanding Common Stock of the Company by reason of stock dividends, split-ups, recapitalizations, reclassifications, combinations or exchanges of shares, separations, reorganizations, liquidations, consolidation, acquisition of the Company, or the like, the number, class and type of shares available upon conversion of this Note and the Conversion Price shall be correspondingly adjusted to give the Holder of the Note, on conversion for the same aggregate Conversion Amount, the total number, class, and type of shares or other property as the Holder would have owned had the Note been converted prior to the event and had the Holder continued to hold such shares until the event requiring adjustment. The form of this Note need not be changed because of any such adjustment.

 

(iii) If at any time following delivery by Holder to the Company of a Notice of Conversion but prior to issuance of the applicable shares upon conversion, the holders of Common Stock of the Company (or any shares of stock or other securities at the time receivable upon the conversion of this Note) shall have received or become entitled to receive, without payment therefor:

 

 
 

 

(A) Common Stock or any shares of stock or other securities which are at any time directly or indirectly convertible into or exchangeable for Common Stock, or any rights or options to subscribe for, purchase or otherwise acquire any of the foregoing by way of dividend or other distribution (other than a dividend or distribution covered in Section 2(b)(i) above),

 

(B) any cash paid or payable otherwise than as a cash dividend, or

 

(C) Common Stock or additional stock or other securities or property (including cash) by way of spinoff, split-up, reclassification, combination of shares or similar corporate rearrangement (other than shares of Common Stock pursuant to Section 2(b)(i) above),

 

then and in each such case, the Holder hereof will be entitled to receive, in addition to the number of shares of Common Stock receivable pursuant to the Notice of Conversion, and without payment of any additional consideration therefor, the amount of stock and other securities and property (including cash in the cases referred to in clauses (B) and (C) above) which such Holder would hold on the date of such exercise had such Holder been the holder of record of such Common Stock as of the date on which holders of Common Stock received or became entitled to receive such shares or all other additional stock and other securities and property.

  

(iv) Upon the occurrence of each adjustment pursuant to this Section 2(b), the Company at its expense will, at the written request of the Holder, promptly compute such adjustment in accordance with the terms of this Note and prepare a certificate setting forth such adjustment, including a statement of the adjusted Conversion Price and adjusted number or type of shares or other securities issuable upon conversion of this Note (as applicable), describing the transactions giving rise to such adjustments and showing in detail the facts upon which such adjustment is based. Upon written request, the Company will promptly deliver a copy of each such certificate to the Holder.

  

(c) Mechanics and Effect of Conversion . No fractional shares of the Company’s Common Stock will be issued upon conversion of this Note. In lieu of any fractional share to which the Holder would otherwise be entitled, the Company will pay to the Holder in cash the amount of the unconverted principal and interest balance of this Note that would otherwise be converted into such fractional share. Upon conversion of this Note pursuant to this Section 2, the Holder shall surrender this Note at the principal offices of the Company, along with a duly executed Conversion Notice in the form attached as Appendix A hereto. At its expense, the Company will, as soon as practicable thereafter, cause to be issued and delivered to such Holder a certificate or certificates for the number of shares to which such Holder is entitled upon such conversion, together with a check payable to the Holder for any cash amounts payable as described herein. Upon conversion of this Note, the Company will be forever released from all of its obligations and liabilities under this Note with regard to that portion of the principal amount and accrued interest being converted including without limitation the obligation to pay such portion of the principal amount and accrued interest.

 

 
 

  

3. Payment Terms . All payments shall be made in lawful money of the United States of America at such place as the Holder hereof may from time to time designate in writing to the Company. Payment shall be credited first to the accrued interest then due and payable and the remainder applied to principal. Prepayment of this Note may be made only upon the written consent of a Majority in Interest (as defined below); provided , that all of the Notes shall be prepaid on a pro rata basis.

 

4. Transfer; Successors and Assigns . The terms and conditions of this Note shall inure to the benefit of and be binding upon the respective successors and assigns of the parties. Notwithstanding the foregoing, the Holder may not assign, pledge, or otherwise transfer this Note without the prior written consent of the Company, except for transfers to affiliates. Subject to the preceding sentence, this Note may be transferred only upon surrender of the original Note for registration of transfer, duly endorsed, or accompanied by a duly executed written instrument of transfer in form satisfactory to the Company. Thereupon, a new convertible promissory note for the same principal amount and interest will be issued to, and registered in the name of, the transferee. Interest and principal are payable only to the registered holder of this Note.

 

5. Governing Law . This Note and all acts and transactions pursuant hereto and the rights and obligations of the parties hereto shall be governed, construed and interpreted in accordance with the laws of the State of Delaware, without giving effect to principles of conflicts of law.

 

6. Notices . Any notice required or permitted by this Note shall be in writing and shall be deemed sufficient upon receipt, when delivered personally or by courier, overnight delivery service or confirmed facsimile or e-mail, or forty-eight (48) hours after being deposited in the U.S. mail as certified or registered mail with postage prepaid, if such notice is addressed to the party to be notified at such party’s address, facsimile number or e-mail as set forth below or as subsequently modified by written notice.

 

7. Amendments and Waivers . Any term of this Note may be amended or waived only with the written consent of the Company and the holders of a majority of the aggregate principal amount of the Notes then outstanding (a “ Majority in Interest ”). Any amendment or waiver effected in accordance with this Section 7 shall be binding upon the Company, the Holder and each transferee of this Note.

 

8. Stockholders, Officers and Directors Not Liable . In no event shall any stockholder, officer or director of the Company be liable for any amounts due or payable pursuant to this Note.

 

 
 

 

 

9. Counterparts . This Note may be executed in two or more counterparts, all of which together shall constitute one and the same instrument. This Note may also be executed and delivered by facsimile or other electronic delivery of signature.

 

10. Titles and Subtitles . The titles and subtitles used in this Note are used for convenience only and are not to be considered in construing or interpreting this Note.

 

[Signature Page Follows]

 

 

 
 

 

This Note is executed and delivered as of the date first set forth above.

 

 

COMPANY:

 

REGENERX BIOPHARMACEUTICALS, INC.

 

 

By:                                                                        

J. J. Finkelstein

President and Chief Executive Officer

 

RegeneRx Biopharmaceuticals, Inc.

15245 Shady Grove Road

Suite 470

Rockville, MD 20850

 

 

 

 

AGREED TO AND ACCEPTED:

 

___________________________

 

 

___________________________

(signature)

 

Address:

 

 

 
 

 

Appendix A

 

Conversion Notice

 

 

 

To convert this Note in accordance with Section 2(a), check this box: o

 

If you want the stock certificate made out in another person’s name fill in the form below:

 

 

Print or type other person’s name, address and zip code:
         
         
         

 

 

Date: _______________________   Your signature:  
    (Sign exactly as your name appears on the Note)

 

 

Deliver this Notice with the original Note to the offices of the Company in accordance with Section 2(c) of the Note.

 

 

 

 

 

Exhibit 10.1

 

 

 

 

 

REGENERX BIOPHARMACEUTICALS, INC.

 

 

 

 

______________________________

 

 

 

 

 

CONVERTIBLE NOTE PURCHASE AGREEMENT

 

 

 

January 7, 2014

  

 
 

 

 

SECTION 1.   DEFINITIONS   1
         
SECTION 2.   ISSUANCE AND SALE OF THE SECURITIES   3
         
SECTION 3.   THE CLOSING   3
         
3.1   Closing    3
         
3.2   Deliveries by the Company   3
         
3.3   Deliveries by the Investor   4
         
SECTION 4.   REPRESENTATIONS, WARRANTIES AND COVENANTS   4
         
4.1   Representations and Warranties of the Company   4
         
4.2   Representations and Warranties of the Investor   6
         
SECTION 5.   CONDITIONS TO CLOSING   7
         
5.1   Conditions to Closing by the Investor   7
         
5.2   Conditions to Closing by the Company   8
         
SECTION 6.   MISCELLANEOUS   8
         
6.1   Waivers and Amendments   8
         
6.2   Costs and Expenses   9
         
6.3   Remedies Cumulative   9
         
6.4   Remedies Not Waived   9
         
6.5   Entire Agreement   9
         
6.6   Specific Performance   9
         
6.7   Governing Law   9
         
6.8   Notices   10
         
6.9   Counterparts   10
         
6.10   Successors and Assigns   10
         
6.11   Third Parties   11
         
6.12   Schedules and Exhibits   11
         
6.13   Headings   11

 

 

- i -
 

 

 

CONVERTIBLE NOTE PURCHASE AGREEMENT

 

THIS CONVERTIBLE NOTE PURCHASE AGREEMENT (this “ Agreement ”), dated as of January 7, 2014, is entered into by and between RegeneRx Biopharmaceuticals, Inc., a Delaware corporation (the “ Company ”), and ____________ (the “ Investor ”).

 

RECITALS

 

Whereas , the Company has authorized the sale and issuance of convertible promissory notes in the form attached hereto as Exhibit A the aggregate principal amount of up to $100,000 (the “ Notes ”) (the securities issuable on conversion of the Notes, the “ Conversion Shares ” and, along with the Notes, the “ Securities ”) for an aggregate purchase amount of up to $100,000, pursuant to the terms of a series of Agreements on substantially identical terms to this Agreement;

 

Whereas , the Investor desires to purchase the Securities on the terms and conditions set forth herein; and

 

Whereas , the Company desires to issue and sell the Securities to the Investor on the terms and conditions set forth herein.

 

Agreement

 

Now, Therefore , in consideration of the foregoing recitals and the mutual promises, representations, warranties, and covenants hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

 

SECTION 1. DEFINITIONS

 

The following terms when used in this Agreement shall have the following respective meanings:

 

Applicable Laws ” has the meaning set forth in Section 4.1(f) hereof.

 

Board of Directors ” means the Board of Directors of the Company.

 

Capital Stock ” means (i) with respect to any Person that is a corporation, any and all shares, interests or equivalents in capital stock (whether voting or nonvoting and whether common or preferred) of such corporation and (ii) with respect to any Person that is not a corporation, any and all partnership, membership, limited liability company or other equity interests of such Person; and in each case, any and all warrants, rights or options to purchase any of the foregoing.

 

Certificate of Incorporation ” means the Certificate of Incorporation of the Company, as in effect and on file with the Secretary of State of the State of Delaware on the date of this Agreement.

 

1
 

 

 

Closing ” has the meaning set forth in Section 3.1 hereof.

 

Closing Date ” has the meaning set forth in Section 3.1 hereof.

 

Common Stock ” means the Common Stock of the Company, par value $0.001 per share.

 

Conversion Shares ” has the meaning set forth in the Preamble.

 

Exchange Act ” means the Securities Exchange Act of 1934, as amended.

 

Governmental Authority ” means the United States, any state, county or municipality, the government of any foreign country, any subdivision of any of the foregoing or any authority, department, commission, board, bureau, agency, court or instrumentality of any of the foregoing.

  

Knowledge of the Company ,” including the terms “ Know ,” “ Known ” and other derivatives thereof, means, with respect to the Company, the actual knowledge, after reasonable investigation, of any Responsible Officer.

 

Lien ” means any mortgage, lien, pledge, security interest, easement, conditional sale or other title retention agreement or other encumbrance of any kind except for liens relating to taxes that have accrued but are not yet payable which do not have a Material Adverse Effect.

 

Material Adverse Effect ” means a material adverse effect upon (i) the condition (financial or otherwise), operations, business, properties or assets of the Company, (ii) the ability of the Company to perform its obligations under this Agreement or any of the other agreements or documents contemplated hereby to which it is a party or (iii) the legality, validity or enforceability of this Agreement or any of the other agreements or documents contemplated hereby or the rights and remedies of the Investor and the other parties hereunder and thereunder.

 

Material Agreements ” has the meaning set forth in Section 4.1(e) hereof.

 

Notes ” has the meaning set forth in the Preamble.

 

Parties ” refers collectively to the Company and the Investor.

 

Person ” means an individual, corporation, partnership, joint venture, trust, unincorporated organization, or Governmental Authority.

 

Purchase Price ” has the meaning set forth in Section 2 hereof.

 

Regulation D ” has the meaning set forth in Section 4.2(c) hereof.

 

Responsible Officer ” means, with respect to the Company, the President and Chief Executive Officer, the Vice President of Clinical and Regulatory Affairs or the Chairman of the Board of Directors.

2
 

 

 

Returns ” has the meaning set forth in Section 4.1(i) hereof.

 

SEC ” means the U.S. Securities and Exchange Commission.

 

SEC Reports ” has the meaning set forth in Section 4.1(h)(i) hereof.

 

Securities ” has the meaning set forth in the Preamble .

 

Securities Act ” means the Securities Act of 1933, as amended.

  

Stockholders ” has the meaning set forth in Section 4.1(b) hereof.

 

Tax ” or “ Taxes ” refers to any and all federal, state, national, local, foreign and other taxes, assessments and other governmental charges, duties, levies, impositions and liabilities relating to taxes, including taxes based upon or measured by gross receipts, income, profits, sales, use and occupation, and value added, ad valorem, transfer, franchise, withholding, payroll, recapture, employment, excise and property taxes, together with all interest, penalties and additions imposed with respect to such amounts and any obligations under any agreements or arrangements with any other person with respect to such amounts and including any liability for taxes of a predecessor entity.

 

SECTION 2. ISSUANCE AND SALE OF THE SECURITIES

 

At the Closing, the Company shall issue and sell to the Investor, and such Investor shall purchase, for an aggregate purchase price of $_______ (the “ Purchase Price ”), from the Company, a Note in the principal amount of $_______.

 

SECTION 3. THE CLOSING

 

3.1 Closing 

 

The closing of the issuance and sale of the Securities pursuant to Section 2 hereof and certain of the other transactions contemplated hereby (the “ Closing ”) shall take place at the offices of Cooley LLP, One Freedom Square, Reston Town Center, 11951 Freedom Drive, Reston, Virginia 20190, or at such other time or place as the Parties shall mutually agree (the actual date being referred to herein as the “ Closing Date ”). The Parties agree that the Closing may occur by facsimile signature and delivery and that the Parties need not appear in person at the Closing.

 

3.2 Deliveries by the Company

 

At or prior to the Closing, the Company shall deliver or cause to be delivered to the Investor the following items:

 

(a) The Note purchased by the Investor hereunder, registered in the name of the Investor and subject to the legends and other restrictions set forth herein;

 

3
 

 

(b) a counterpart of this Agreement duly executed by the Company. 

 

3.3 Deliveries by the Investor

 

At or prior to the Closing, the Investor shall deliver or cause to be delivered to the Company the following items:

 

(a) payment of the Purchase Price in immediately available funds by wire transfer to an account designated in writing by the Company prior to the Closing Date;

 

(b) a fully completed and duly executed Accredited Investor Certification in the form attached hereto as E xhibit B ; and

 

(c) a counterpart of this Agreement duly executed by the Investor.

 

SECTION 4. REPRESENTATIONS, WARRANTIES AND COVENANTS

 

4.1 Representations and Warranties of the Company

 

In order to induce the Investor to purchase the Securities it is purchasing hereunder, the Company represents and warrants to the Investor as of the date hereof that:

 

(a) Organization and Standing . The Company is duly incorporated and validly existing under the laws of the State of Delaware and has all requisite corporate power and authority to own or lease its properties and assets and to conduct its business as it is presently being conducted.

 

(b) Capitalization . The outstanding shares of Capital Stock are all duly and validly authorized and issued, fully paid and nonassessable, and based in part on the representations of the stockholders of the Company (the “ Stockholders ”) made in connection with the issuance thereof, were issued in compliance with all applicable federal and state securities laws.

 

(c) Capacity of the Company; Consents; Execution of Agreements . The Company has all requisite power, authority and capacity to enter into this Agreement and to perform the transactions and obligations to be performed by it hereunder. The execution and delivery of this Agreement and any agreements contemplated hereby by the Company, and the performance by the Company of the transactions and obligations contemplated hereby and thereby, including, without limitation, the issuance and delivery of the Securities to the Investor, has been duly authorized by all requisite action of the Company and Stockholders. This Agreement has been duly executed and delivered by a duly authorized officer of the Company and constitutes a valid and legally binding agreement of the Company, enforceable in accordance with its respective terms, except as enforcement thereof may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws of the United States (both state and federal), affecting the enforcement of creditors’ rights or remedies in general and general equity principles.

 

 

4
 

 

(d) Status of the Conversion Shares; Reservation of Common Stock . The Conversion Shares to be issued and purchased hereunder, when issued by the Company to the Investor and paid for by the Investor pursuant to the terms of this Agreement and the Note will (i) be duly authorized, validly issued, fully paid and nonassessable, (ii) based on the Investor’s representations in Section 4.2, have been issued in compliance with all applicable United States federal and state securities laws and (iii) be free and clear of all Liens. The Company has available sufficient shares of Common Stock for issuance pursuant to the terms of this Agreement.

 

(e) Conflicts; Defaults . The execution and delivery of this Agreement by the Company and the performance by the Company of the transactions and obligations contemplated hereby to be performed by it will not (i) materially violate, conflict with, or constitute a default under any of the terms or provisions of, the Certificate of Incorporation, the bylaws, or any provisions of, or result in the acceleration of any obligation under, any material contract, note, debt instrument, security agreement, or other instrument to which the Company is a party or by which the Company, or any of their assets is bound (collectively, the “ Material Agreements ”); (ii) result in the creation or imposition of any Liens or claims upon the Company’s assets or upon the Company’s Common Stock; (iii) assuming the accuracy of the Investor’s representations in Section 4.2, constitute a material violation of any law, statute, judgment, decree, order, rule, or regulation of a Governmental Authority applicable to the Company; or (iv) constitute an event which, after notice or lapse of time or both, would result in any of the foregoing. The Company is not presently in violation of its Certificate of Incorporation or bylaws.

 

(f) Compliance with Laws . The Company is not in violation of, nor do any of its respective operations violate in any respect, any statute, law, or regulation of any Governmental Authority applicable to the Company (“ Applicable Laws ”), which violation would have a Material Adverse Effect.

 

(g) Litigation . As of the date hereof: (i) the Company is not subject to any order of, or written agreement or memorandum of understanding with, any Governmental Authority which would have a Material Adverse Effect; (ii) there are no material actions, suits, claims, investigations, or proceedings pending at law or in equity or before or by any Governmental Authority, or, to the Knowledge of the Company, threatened, against the Company or any of its assets or properties or the transactions contemplated by this Agreement, and to the Knowledge of the Company, there exist no facts or circumstances which reasonably could be anticipated to result in any such action, suit, claim, investigation, or proceeding; and (iii) no Person has asserted, and, to the Knowledge of the Company, no Person has a valid basis upon which to assert, any claims against the Company that would materially adversely affect the transactions contemplated by this Agreement or result in or form the basis of any such action, suit, claim, investigation or proceeding. There is no material action, suit, proceeding or investigation by the Company currently pending or which the Company intends to initiate.

 

(h) Securities Laws .

 

(i) The Company has filed all forms, reports and documents with the SEC required to be filed by it pursuant to the federal securities laws and the SEC rules and regulations thereunder, all of which complied in all material respects with all applicable requirements of the Securities Act and the Exchange Act (collectively, the “ SEC Reports ”). None of the SEC Reports, including, without limitation, any financial statements or schedules included therein, at the time filed (or if amended or superseded by a filing prior to the date of this Agreement, then on the date of such filing) contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of circumstances under which they were made, not misleading.

 

5
 

 

(ii) Based on the Investor’s representations in Section 4.2, no consent, authorization, approval, permit, or order of or filing with any Governmental Authority is required in order for the Company to execute and deliver this Agreement or in order for the Company to offer, issue, sell, or deliver the Securities. Based in part on the representations of the Investor and under the circumstances contemplated hereby and under current laws and regulations, the offer, issuance, sale and delivery of the Securities to the Investor is exempt from the registration requirements of the Securities Act.

 

(i) Taxes . The Company has timely filed or caused to be filed with the appropriate taxing authority all federal, state, national, local and foreign returns, estimates, information statements and reports (“ Returns ”) relating to Taxes required to be filed by the Company on or prior to the Closing Date. The Returns have accurately reflected in all material respects and will accurately reflect in all material respects all liability for Taxes of the Company for the periods covered thereby.

 

4.2 Representations and Warranties of the Investor

 

The Investor hereby represents and warrants to the Company that as of the date hereof:

 

(a) Investment Intent . The Securities to be purchased by the Investor hereunder are being purchased for its own account and not with the view to, or for resale in connection with, any distribution or public offering thereof within the meaning of the Securities Act. The Investor understands that the Securities have not been registered under the Securities Act by reason of their issuance in transactions exempt from the registration and prospectus delivery requirements of the Securities Act pursuant to Section 4(a)(2) thereof. The Investor further understands that the certificates representing the Conversion Shares that may be issued pursuant to the conversion of the Note will bear the following legend and the Investor agrees that it will hold such shares subject thereto:

 

“THESE SECURITIES HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT” ), OR ANY APPLICABLE STATE SECURITIES LAWS AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN COMPLIANCE WITH APPLICABLE STATE SECURITIES LAWS OR BLUE SKY LAWS.”

 

6
 

 

(b) Capacity of the Investor; Execution of Agreement . The Investor has all requisite power, authority and capacity to enter into this Agreement, deliver the Purchase Price, and to perform the transactions and obligations to be performed by it hereunder. This Agreement has been duly authorized, executed and delivered by them and constitutes its valid and legally binding obligation, enforceable in accordance with its terms, except as enforcement thereof may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws, both state and federal, affecting the enforcement of creditors’ rights or remedies in general from time to time in effect and the exercise by courts of equity powers or their application of principles of public policy.

 

(c) Accredited Investor . The Investor is an “accredited investor” as defined in Rule 501(a) of Regulation D promulgated under the Securities Act (“ Regulation D ”).

 

(d) Suitability and Sophistication . (i) The Investor has such knowledge and experience in financial and business matters that it is capable of independently evaluating the risks and merits of purchasing the Securities; (ii) the Investor has independently evaluated the risks and merits of purchasing the Securities and has independently determined that the Securities are a suitable investment for it; and (iii) the Investor has sufficient financial resources to bear the loss of their entire investment in the Securities.

 

(e) Receipt of Information . The Investor believes, after due inquiry and investigation, that it has received all of the information that it considers necessary or appropriate for deciding whether to purchase the Securities. The Investor further represents that it has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of the Securities and the business, properties, prospects and financial condition of the Company and to obtain additional information (to the extent the Company possessed such information or could acquire it without unreasonable effort or expense) necessary to verify the accuracy of any information furnished to the Investor. The foregoing, however, does not limit or modify the representations and warranties of the Company in Section 4 of this Agreement or the right of the Investor to rely thereon.

 

(f) Independent Existence . The Investor was not formed for the specific purpose of purchasing the Securities.

 

SECTION 5. CONDITIONS TO CLOSING

 

5.1 Conditions to Closing by the Investor

 

The obligations of the Investor to consummate the purchase of the Securities pursuant to Section 2 hereof and certain of the transactions contemplated by this Agreement are subject to the satisfaction on or prior to the Closing Date of the following conditions, any of which may be waived in whole or in part in writing by the Investor: 

 

(a) all representations and warranties of the Company contained in this Agreement shall be true and correct as of the date of this Agreement and as of the Closing Date as though made anew as of such date (unless another date is specified);

 

7
 

 

(b) the Company shall have delivered to the Investor the items required by Section 3.2 of this Agreement;

 

(c) the Company shall have performed and complied with all agreements and conditions required by this Agreement to be performed and complied with by it prior to or as of the Closing Date; and

 

(d) all pre-issuance registrations, qualifications, permits and approvals required, if any, under applicable state securities laws or stock exchange listing rules for the lawful execution and delivery of this Agreement and the offer, sale, issuance and delivery of the Securities shall have been obtained.

 

5.2 Conditions to Closing by the Company

 

The obligations of the Company to consummate the issuance and sale of the Securities pursuant to Section 2 hereof and certain of the transactions contemplated by this Agreement are subject to the satisfaction on or prior to the Closing Date of the following conditions, any of which may be waived in whole or in part in writing by the Company:

 

(a) all representations and warranties of the Investor contained in this Agreement shall be true and correct as of the date of this Agreement and as of the Closing Date as though made anew as of such date;

 

(b) the Investor shall have delivered to the Company the items required by Section 3.3 of this Agreement;

 

(c) all pre-issuance registrations, qualifications, permits and approvals required, if any, under applicable state securities laws or stock exchange listing rules for the lawful execution and delivery of this Agreement and the offer, sale, issuance and delivery of the Securities shall have been obtained; and

 

(d) the Investor shall have performed and complied with all agreements and conditions required by this Agreement to be performed and complied with by it prior to or as of the Closing Date.

 

SECTION 6. MISCELLANEOUS

 

6.1 Waivers and Amendments

 

This Agreement may be amended or modified in whole or in part only by a writing which makes reference to this Agreement that is executed by the Investor and the Company. The obligations of any Party hereunder may be waived (either generally or in a particular instance and either retroactively or prospectively) only with the written consent of the party claimed to have given the waiver; provided, however, that any waiver by any party of any violation of, breach of, or default under any provision of this Agreement or any other agreement provided for herein shall not be construed as, or constitute, a continuing waiver of such provision, or waiver of any other violation of, breach of or default under any other provision of this Agreement or any other agreement provided for herein.

 

8
 

 

6.2 Costs and Expenses

 

Each party agrees to pay its own costs and expenses in connection with the preparation, execution and delivery of this Agreement and other instruments and documents to be delivered hereunder and thereunder.

 

6.3 Remedies Cumulative

 

No specific right, power, or remedy conferred by this Agreement shall be exclusive, and each such right, power, or remedy shall be cumulative and in addition to every other right, power, or remedy, whether conferred hereby or by any security of the Company or now or hereafter available, at law or in equity, by statute or otherwise.

 

6.4 Remedies Not Waived

 

No course of dealing between the Company and the Investor, and no delay in exercising any right, power, or remedy conferred hereby or by any security issued by the Company, or now or hereafter available at law or in equity, by statute or otherwise, shall operate as a waiver of or otherwise prejudice any such right, power, or remedy.

 

6.5 Entire Agreement

 

This Agreement and the other agreements and instruments expressly provided for herein, together set forth the entire understanding of the parties hereto and supersede in their entirety all prior contracts, agreements, arrangements, communications, discussions, representations and warranties, whether oral or written, among the parties with respect to the subject matter hereof.

 

6.6 Specific Performance

 

The Company and the Investor acknowledge and agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with the specific terms hereof or were otherwise breached. It is accordingly agreed that, to the fullest extent permitted by law or equity, each of the parties shall be entitled to an injunction or injunctions to prevent or cure breaches of the provisions of this Agreement and to enforce specifically the terms and provisions hereof, this being in addition to any other remedy to which the parties may be entitled by law or equity.

 

6.7 Governing Law

 

This Agreement shall in all respects be governed by and construed in accordance with the internal substantive laws of the State of Delaware without giving effect to the principles of conflicts of law thereof.

 

9
 

 

 

6.8 Notices

 

Any notice, request or other communication required or permitted hereunder shall be in writing and be deemed to have been duly given (a) when personally delivered or sent by facsimile transmission (the receipt of which is confirmed in writing), (b) one business day after being sent by a nationally recognized overnight courier service or (c) three business days after being sent by registered or certified mail, return receipt requested, postage prepaid, to the parties at their respective addresses set forth below.

 

If to the Company:

 

RegeneRx Biopharmaceuticals, Inc.

15245 Shady Grove Road

Suite 470

Rockville, MD 20850

Attention: J.J. Finkelstein

Facsimile: 301-208-9194

 

With a copy, which shall not constitute notice, to:

Cooley LLP

One Freedom Square, Reston Town Center

11951 Freedom Drive

Reston, VA 20190

Attention: Darren K. DeStefano, Esq.

Facsimile: 703-456-8100

 

If to the Investor:

 

To the address set forth below the Investor’s name on the signature page of this Agreement

 

Any party by written notice to the others may change the address or the persons to whom notices or copies thereof shall be directed.

 

6.9 Counterparts

 

This Agreement may be executed in counterparts, each of which shall be deemed to be an original, and all of which together shall constitute one and the same instrument.

 

6.10 Successors and Assigns

 

This Agreement shall be binding upon and shall inure to the benefit of the parties hereto and their respective successors and assigns.

 

 

10
 

 

6.11 Third Parties

 

Nothing expressed or implied in this Agreement is intended, or shall be construed, to confer upon or give any Person other than the parties hereto any rights or remedies under or by reason of this Agreement.

 

6.12 Schedules and Exhibits

 

The schedules and exhibits attached to this Agreement are incorporated herein and shall be part of this Agreement for all purposes.

 

6.13 Headings

 

The headings in this Agreement are solely for convenience of reference and shall not be given any effect in the construction or interpretation of this Agreement.

 

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

11
 

 

 

 

IN WITNESS WHEREOF , the parties have duly executed, or have caused their duly authorized officer or representative to execute, this Securities Purchase Agreement as of the date first above written.

 

REGENERX BIOPHARMACEUTICALS, INC.

 

By: ______________________________

Name: J.J. Finkelstein

Title: President and Chief Executive Officer

 

 

1
 

 

IN WITNESS WHEREOF , the parties have duly executed, or have caused their duly authorized officer or representative to execute, this Securities Purchase Agreement as of the date first above written.

 

 

Name of Purchaser: __________________________

 

Signature of Authorized Signatory of Purchaser : _________________________________

 

Name of Authorized Signatory: _________________

 

Title of Authorized Signatory: _______

 

Email Address of Authorized Signatory: __________________

 

Facsimile Number of Authorized Signatory: __________________________

 

Address for Notice of Purchaser:

 

___________________________________________

 

Address for Delivery of Securities for Purchaser (if not same as address for notice):

 

____________________________________________

 

 

2
 

 

Exhibit A

 

FORM OF NOTE

 

[ATTACHED]

 

3
 

 

 

Exhibit B

 

 

 

4
 

 

 

ACCREDITED INVESTOR CERTIFICATION

 

The undersigned represents and warrants to RegeneRx Biopharmaceuticals, Inc. (the “ Company ”) that the undersigned fits within each category marked below, and that for any category marked, he, she or it has truthfully set forth any description required as provided for below. ALL INFORMATION WILL BE KEPT STRICTLY CONFIDENTIAL. The undersigned agrees to furnish any additional information that the Company deems necessary in order to verify the answers set forth below.

 

(PLEASE MARK EACH CATEGORY APPLICABLE TO YOU)

 

¨ The undersigned is an individual (not a partnership, corporation, etc.) whose individual net worth, or joint net worth with his or her spouse, presently exceeds $1,000,000.

 

Explanation. In calculating net worth you may include equity in personal property and real estate, including your principal residence, cash, short-term investments, stock and securities. Equity in personal property and real estate should be based on the fair market value of such property minus debt secured by such property.

 

¨ The undersigned is an individual (not a partnership, corporation, etc.) who had an income in excess of $200,000 in each of the two most recent years, or joint income with his or her spouse in excess of $300,000 in each of those years (in each case, including foreign income, tax exempt income and full amount of capital gains and losses, but excluding any income of other family members and any unrealized capital appreciation), and has a reasonable expectation of reaching the same income level in the current year.

 

¨ The undersigned is a director or executive officer of the Company.

 

¨ The undersigned is either: (a) a bank as defined in Section 3(a)(2) of the Securities Act of 1933, as amended (the “ Act ”); (b) a savings and loan association or other institution as defined in Section 3(a)(5)(A) of the Act, whether acting in its individual or fiduciary capacity; (c) a broker dealer registered pursuant to Section 15 of the Securities Exchange Act of 1934; (d) an insurance company as defined in Section 2(13) of the Act; (e) an investment company registered under the Investment Company Act of 1940 or a business development company as defined in Section 2(a)(48) of the Act; (f) a small business investment company licensed by the U.S. Small Business Administration under Section 301(c) or (d) of the Small Business Investment Act of 1958; (g) a plan established and maintained by a state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions, for the benefit of its employees, if such a plan has total assets in excess of $5,000,000; or (h) an employee benefit plan within the meaning of the Employee Retirement Income Security Act of 1974 (“ ERISA ”), if the investment decision is made by a plan fiduciary, as defined in Section 3(21) of ERISA, which is either a bank, savings and loan association, insurance company or registered investment advisor, or if the employee benefit plan has total assets in excess of $5,000,000, or, if a self-directed plan, with investment decisions made solely by persons that are accredited investors, as defined in Rule (501)(a) promulgated under the Act.
     
     
     

 

(describe entity)

 

¨ The undersigned is a private business development company as defined in Section 202(a)(22) of the Investment Advisers Act of 1940.
     
     

  

(describe entity)

 

 

5
 

 

¨ The undersigned is an organization within the meaning of Section 501(c)(3) of the Internal Revenue Code, a corporation, a business trust, or a partnership, not formed for the specific purpose of acquiring the Securities, with total assets in excess of $5,000,000.
     
     

 

(describe entity)

 

¨ The undersigned is a trust with total assets in excess of $5,000,000, not formed for the specific purpose of acquiring the Securities, whose investments are directed by a “ sophisticated person ” as described in Rule 506(b)(2)(ii) promulgated under the Act.

 

¨ The undersigned is an entity, all the equity owners of which are “ accredited investors ” within one or more of the above categories. If relying upon this category alone, each equity owner must complete a separate copy of this Certificate.
     
     

 

(describe entity)

 

¨ The undersigned does not meet the criteria of any of the categories listed above.

 

 

THE UNDERSIGNED UNDERSTANDS THAT THE COMPANY WILL RELY ON THE FOREGOING REPRESENTATIONS TO, AMONG OTHER THINGS, MAINTAIN THE EXEMPTION FOR THE ISSUANCE OF THE SECURITIES FROM THE REQUIREMENT TO REGISTER SUCH SECURITIES UNDER THE ACT.

 

The answers to the foregoing questions are correctly stated to the best of my knowledge, information and belief. I hereby agree to notify the Company promptly of any changes in the foregoing information.

 

Dated: ________________

 

Name of Purchaser: __________________________________

 

Signature of Authorized Signatory of Purchaser : _________________________________

 

Name of Authorized Signatory: ____________________

 

Title of Authorized Signatory: ________

 

6

Exhibit 10.2

 

 

 

 

January 7, 2014

 

Mr. J.J. Finkelstein

3910 East-West Highway

Chevy Chase, MD 20815

 

Re: Third Amendment to Temporary Employment Terms and to Amended and Restated Change in Control Agreement

 

Dear J.J.:

 

This letter agreement (the “ Amendment ”) amends certain of the terms and conditions relating to your employment with RegeneRx Biopharmaceuticals, Inc. (“ Company ”) that were set forth in that Tempor ary Employment Terms Letter Agreement dated July 2, 2012, executed by you and the Company, as amended by the First and Second Amendments to Temporary Employment Terms effective January 1, 2013 and July 1, 2013, respectively (collectively, the “ Employment Agreement ”) and amends certain terms of the Amended and Restated Change in Control Agreement between you and RegeneRx Biopharmaceuticals, Inc . dated July 2, 2012, as amended (the “ CIC Agreement ”). As provided at the end of this letter, you may accept this Amendment by signing and returning to us a counterpart copy of this letter, which signature and return will result in this Amendment being binding between the Company and you as to the matters set forth herein, as of January 1, 2014 (the “ Effective Date ”).

 

The Employment Agreement and the CIC Agreement shall be amended by replacing the date of “December 31, 2103” throughout the Employment Agreement and the CIC Agreement with “June 30, 2014.” Except as herein modified or amended, no other term or provision of the Employment Agreement or the CIC Agreement is amended or modified in any respect. Nothing in this Amendment is intended to alter the at-will nature of your employment with the Company.

 

This Amendment, together with your Employment Agreement and its exhibits (as expressly modified herein) and the CIC Agreement, constitute the complete, final and exclusive embodiment of the entire agreement between the Company and you with regard to matters set forth herein, and supersede and replace any other agreements (whether written or unwritten) you may have with the Company with regard to matters set forth herein. This Amendment will bind the heirs, personal representatives, successors and assigns of both you and the Company, and inure to the benefit of both you and the Company, their heirs, successors and assigns. If any provision of this Amendment is determined to be invalid or unenforceable, in whole or in part, this determination shall not affect any other provision of this Amendment and the provision in question shall be modified so as to be rendered enforceable in a manner consistent with the intent of the parties insofar as possible under applicable law. This Amendment may be executed in counterparts which shall be deemed to be part of one original, and facsimile signatures shall be equivalent to original signatures.

 

RegeneRx Biopharmaceuticals, Inc. · 15245 Shady Grove Road, Suite 470, Rockville, MD 20850

PHONE 301.208.9191 · FAX 301.208.9194 · WEB www.regenerx.com

 

 
 

 

To indicate your understanding and acceptance of this Amendment, please sign and date below, and return this Amendment to me. You may retain the enclosed additional copy of this Amendment for your files.

 

Sincerely,

 

RegeneRx Biopharmaceuticals, Inc .

 

 

By: /s/ Allan L. Goldstein                 

Name: Allan L. Goldstein

Title: Chairman

 

Agreed to and Accepted:

 

 

/s/J. J. Finkelstein                          

J. J. Finkelstein

 

January 7, 2014                              

Date

 

 

2

Exhibit 10.3

 

 

J anuary 7, 2014

 

Dr. Allan L. Goldstein

P.O. Box 29

Reedville, VA 22539

 

Re: Third Amendment to Temporary Employment Terms and to Amended and Restated Change in Control Agreement

 

Dear Allan:

 

This letter agreement (the “ Amendment ”) amends certain of the terms and conditions relating to your employment with RegeneRx Biopharmaceuticals, Inc. (“ Company ”) that were set forth in that Tempor ary Employment Terms Letter Agreement dated July 2, 2012, executed by you and the Company, as amended by the First and Second Amendments to Temporary Employment Terms effective January 1, 2013 and July 1, 2013, respectively (collectively, the “ Employment Agreement ”) and amends certain terms of the Amended and Restated Change in Control Agreement between you and RegeneRx Biopharmaceuticals, Inc . dated July 2, 2012, as amended (the “ CIC Agreement ”). As provided at the end of this letter, you may accept this Amendment by signing and returning to us a counterpart copy of this letter, which signature and return will result in this Amendment being binding between the Company and you as to the matters set forth herein, as of January 1, 2014 (the “ Effective Date ”).

 

The Employment Agreement and the CIC Agreement shall be amended by replacing the date of “December 31, 2013” throughout the Employment Agreement and the CIC Agreement with “June 30, 2014.” Except as herein modified or amended, no other term or provision of the Employment Agreement or the CIC Agreement is amended or modified in any respect. Nothing in this Amendment is intended to alter the at-will nature of your employment with the Company.

 

This Amendment, together with your Employment Agreement and its exhibits (as expressly modified herein) and the CIC Agreement, constitute the complete, final and exclusive embodiment of the entire agreement between the Company and you with regard to matters set forth herein, and supersede and replace any other agreements (whether written or unwritten) you may have with the Company with regard to matters set forth herein. This Amendment will bind the heirs, personal representatives, successors and assigns of both you and the Company, and inure to the benefit of both you and the Company, their heirs, successors and assigns. If any provision of this Amendment is determined to be invalid or unenforceable, in whole or in part, this determination shall not affect any other provision of this Amendment and the provision in question shall be modified so as to be rendered enforceable in a manner consistent with the intent of the parties insofar as possible under applicable law. This Amendment may be executed in counterparts which shall be deemed to be part of one original, and facsimile signatures shall be equivalent to original signatures.

 

RegeneRx Biopharmaceuticals, Inc. · 15245 Shady Grove Road, Suite 470, Rockville, MD 20850

PHONE 301.208.9191 · FAX 301.208.9194 · WEB www.regenerx.com

 

 

 
 

 

To indicate your understanding and acceptance of this Amendment, please sign and date below, and return this Amendment to me. You may retain the enclosed additional copy of this Amendment for your files.

 

Sincerely,

 

RegeneRx Biopharmaceuticals, Inc .

 

 

By: J.J. Finkelstein                                   

J.J. Finkelstein

President and Chief Executive Officer

 

Agreed to and Accepted:

 

 

/s/Allan L. Goldstein                             

Allan L. Goldstein

 

January 7, 2014                                       

Date

 

2